Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Article | July 23, 2015

How To Avoid FDA Regulation Of Your Mobile Medical App

Blog | July 22, 2015

Amgen v. Sandoz: Federal Circuit Weighs In on the BPCIA Riddle

Blog | July 21, 2015

Exclusion of Patentee's Damages Expert Not Sufficient to Justify Granting Summary Judgment

Blog | July 21, 2015

Claims Should Be Broadly Construed to Include Their Full Plain Meaning Where There Is No Disclaimer or Lexicography

Blog | July 10, 2015

NDCA bars negative NPE terminology; allows product revenue and settlement agreements

Blog | July 08, 2015

Software Claim Addressing Concepts Long Known in Other Fields and Lacking Other Inventive Concept Is Not Patent Eligible

Blog | July 07, 2015

FDA's Latest ANDA Guidance: Patent Carve Outs Become a Guessing Game

Blog | July 06, 2015

35 U.S.C. § 101 Practice in the Eastern District of Texas

Blog | July 03, 2015

DDE excludes revenues & profits due to failed apportionment, allows do-over

Blog | July 02, 2015

Nevada court imposes 3X post-judgment royalty in lieu of injunction

Blog | July 01, 2015

Utah court allows evidence of minimum royalty payments by third parties

Blog | June 25, 2015

Predictions for the Outcome of Amgen v. Sandoz